GE HealthCare Technologies Inc. GEHC
Verdict: Strong sell. Fair value $64.05 against a price of $85.04 on 6 Jan 2026, 25% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. The OCF / Net Income ratio deteriorated significantly from a strong 1.34 in 2023 to 0.98 in 2024..... The accruals ratio for 2024 is +0.0012, calculated as (Net Income $1.99B - OCF $1.95B) / Total....
Main risks
- High Leverage: The Debt-to-Equity ratio is over 1.1 and the estimated Total Debt/EBITDA ratio is high at approximately 5.1x, indicating significant financial risk and limited flexibility.
- Decelerating Growth & Declining FCF: Annual revenue growth has slowed to less than 1%, and TTM Free Cash Flow ($1.40B) has declined from its peak of $1.80B in 2022, suggesting potential business pressure.
- Weak Capital Allocation Returns: The estimated ROIC (~7.0%) and ROIIC (~8.9%) are low. This suggests that incremental capital invested in the business is not generating strong returns, questioning long-term value creation.
- The OCF / Net Income ratio deteriorated significantly from a strong 1.34 in 2023 to 0.98 in 2024....
- Intense competitive environment
- The OCF / Net Income ratio deteriorated significantly from a strong 1.34 in 2023 to 0.98 in 2024. This indicates that for the most recent year, reported earnings are not fully converting into cash, a potential sign of aggressive revenue recognition or working capital strain.